NasdaqGS:MYGN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. More Details

Rewards

Trading at 40.5% below our estimate of its fair value

Risk Analysis

No risks detected for MYGN from our risk checks.


Snowflake Analysis

Fair value with mediocre balance sheet.


Similar Companies

Share Price & News

How has Myriad Genetics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MYGN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-5.6%

MYGN

6.6%

US Biotechs

1.8%

US Market


1 Year Return

-54.1%

MYGN

31.5%

US Biotechs

14.2%

US Market

Return vs Industry: MYGN underperformed the US Biotechs industry which returned 31.5% over the past year.

Return vs Market: MYGN underperformed the US Market which returned 14.2% over the past year.


Shareholder returns

MYGNIndustryMarket
7 Day-5.6%6.6%1.8%
30 Day-12.1%-0.9%0.04%
90 Day4.6%-1.8%9.8%
1 Year-54.1%-54.1%33.7%31.5%16.7%14.2%
3 Year-62.9%-62.9%18.4%12.7%41.6%32.2%
5 Year-67.4%-67.4%16.2%8.2%90.9%69.5%

Price Volatility Vs. Market

How volatile is Myriad Genetics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Myriad Genetics undervalued compared to its fair value and its price relative to the market?

40.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MYGN ($12.54) is trading below our estimate of fair value ($21.08)

Significantly Below Fair Value: MYGN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MYGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MYGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYGN is good value based on its PB Ratio (1x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Myriad Genetics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

70.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MYGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MYGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MYGN's revenue (5.1% per year) is forecast to grow slower than the US market (9.7% per year).

High Growth Revenue: MYGN's revenue (5.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (6.8%).


Next Steps

Past Performance

How has Myriad Genetics performed over the past 5 years?

-50.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MYGN is currently unprofitable.

Growing Profit Margin: MYGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYGN is unprofitable, and losses have increased over the past 5 years at a rate of 50% per year.

Accelerating Growth: Unable to compare MYGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: MYGN has a negative Return on Equity (-21.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is Myriad Genetics's financial position?


Financial Position Analysis

Short Term Liabilities: MYGN's short term assets ($331.7M) exceed its short term liabilities ($147.0M).

Long Term Liabilities: MYGN's short term assets ($331.7M) do not cover its long term liabilities ($339.4M).


Debt to Equity History and Analysis

Debt Level: MYGN's debt to equity ratio (24.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if MYGN's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: MYGN's debt is well covered by operating cash flow (27%).

Interest Coverage: Insufficient data to determine if MYGN's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Myriad Genetics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MYGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Paul Diaz (58 yo)

0.083

Tenure

Mr. Paul J. Diaz serves as Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He served as a Partner at Cressey & Company LP since September 2017. Since August ...


Leadership Team

NamePositionTenureCompensationOwnership
R. Riggsbee
Executive VP5.92yrsUS$3.14m0.082%
$ 766.0k
Alexander Ford
Chief Operating Officer0.67yrUS$3.23m0.083%
$ 775.2k
Jerry Lanchbury
Chief Scientific Officer10.58yrsUS$2.69m0.16%
$ 1.5m
Paul Diaz
CEO, President & Director0.083yrno datano data
Scott Gleason
Senior Vice President of Investor Relationsno datano datano data
Benjamin Jackson
Executive VP1.17yrsno data0.084%
$ 784.2k
Clivetty Martinez
Chief Compliance Officer1.67yrsno datano data
Jayne Hart
Executive Vice President of Human Resources9.33yrsno datano data
Paul Parkinson
Executive Vice President of Reimbursement Strategy4yrsno datano data
Mark Verratti
President of Myriad Neuroscience & Myriad Autoimmune3.08yrsno data0.039%
$ 364.4k
Nicole Lambert
Group President of Myriad Oncology1.42yrsno data0.089%
$ 837.6k
Mark Pollack
Chief Medical Officer0.67yrno datano data

1.7yrs

Average Tenure

52.5yo

Average Age

Experienced Management: MYGN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul Diaz
CEO, President & Director0.083yrno datano data
Daniel Spiegelman
Director0.33yrno datano data
Lawrence Best
Independent Director11yrsUS$380.49k0.066%
$ 615.8k
Walter Gilbert
Independent Vice Chairmanno dataUS$369.99k0.057%
$ 532.5k
John Henderson
Independent Director16.33yrsUS$482.49k0.089%
$ 832.7k
Dennis Langer
Independent Director16.33yrsUS$392.49k0.050%
$ 469.2k
Lee Newcomer
Independent Director1yrno datano data
Daniel Skovronsky
Director0.17yrno datano data
Colleen Reitan
Independent Director1yrno datano data
Heinrich Dreismann
Independent Director10.25yrsUS$384.99k0.058%
$ 540.5k
S. Phanstiel
Independent Chair of the Board0.50yrUS$399.49k0.045%
$ 419.1k
Rashmi Kumar
Directorno datano datano data

1.0yrs

Average Tenure

64yo

Average Age

Experienced Board: MYGN's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MYGN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Myriad Genetics, Inc.
  • Ticker: MYGN
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$936.855m
  • Shares outstanding: 74.71m
  • Website: https://myriad.com

Number of Employees


Location

  • Myriad Genetics, Inc.
  • 320 Wakara Way
  • Salt Lake City
  • Utah
  • 84108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 1995
MYDDB (Deutsche Boerse AG)YesCommon StockDEEUROct 1995
MYDXTRA (XETRA Trading Platform)YesCommon StockDEEUROct 1995
0K3WLSE (London Stock Exchange)YesCommon StockGBUSDOct 1995

Biography

Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hered ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 06:04
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.